Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply From examining our Figure 1,1 Dr Fagan incorrectly infers a steep negative relationship between payment amounts in the $0 to $20 000 payment range and branded statin prescribing. In fact, the relationship is flat, with 0.03% additional brand-name prescribing for every $1000 received (95% CI, −0.31 to 0.37; P = .86). Dr Fagan arrives at the same conclusion we originally expressed: that the positive association between publicly reported financial ties to the pharmaceutical industry and higher brand-name statin prescribing was driven by physicians receiving the largest payments. Despite Dr Fagan’s minimization of this finding, we believe it is important, since prescribing a brand-name statin instead of an equally effective generic can lead to worse cardiovascular outcomes.2
Yeh JS, Franklin JM, Kesselheim AS. Payments to Physicians, Prescribing Rates, and More Appropriate Conclusions—Reply. JAMA Intern Med. 2016;176(10):1577. doi:10.1001/jamainternmed.2016.5802
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: